Table 1.
Epstein–Barr (EBV)-associated lymphomas in immunocompetent and immunocompromised hosts.
| Immunocompetent Host | Immunocompromised Hosts | ||||
|---|---|---|---|---|---|
| Lymphoma | EBV Association | Latency Program | Lymphoma | EBV Association | Latency Program |
| BL (endemic) | 100% | I or Wp- restricted | PTLD, B-cell | >90% | III |
| BL (sporadic) | 15–85% | I | BL (HIV) | 25–35% | I |
| Classical HL | 40% | II | HL (HIV) | >80% | II |
| DLBCL associated with chronic inflammation | ~70% | II | PEL (primary effusion lymphoma) | >80% | I |
| EBV-positive DLBCL of the elderly | 100% | II | Plasmablastic lymphoma | ~70% | I or II |
| Lymphomatoid granulomatosis | 100% | II | Plasmablastic lymphoma, oral type (HIV) | 100% | I |
| Angioimmunoblastic T-cell lymphoma * | >90% | II | Primary CNS lymphoma (HIV) | 100% | III |
| Extranodal NK/T-cell lymphoma, nasal type * | 100% | II | NHLs with primary immune disorders | >90% | III |
| Aggressive NK-cell leukemia * | >90% | II | Iatrogenic immunodeficiency lymphoma | 40–50% | III |
| PTLD, NK/T-cell * | >70% | III | |||